Management of kidney cancer patients: 2018 guidelines of the Italian Medical Oncology Association (AIOM)-Reference-Cited by-同舟云学术

Management of kidney cancer patients: 2018 guidelines of the Italian Medical Oncology Association (AIOM)

Published:2019-07 Issue:4_suppl Volume:105 Page:3-12
ISSN:0300-8916
Container-title:Tumori Journal
language:en
Short-container-title:Tumori Journal

Author:

Giuseppa Vitale Maria¹,Bracarda Sergio²,Cosmai Laura³,Crocetti Emanuele⁴,Di Lorenzo Giuseppe⁵,Lapini Alberto⁶,Mandressi Alberto⁷,Martorana Giuseppe⁸,Masini Cristina⁹,Montironi Rodolfo¹⁰,Ortega Cinzia¹¹,Passalacqua Rodolfo¹²,Porta Camillo¹³,Procopio Giuseppe¹⁴,Sepe Pierangela¹⁴,Romano Luigia¹⁵,Luigi Pappagallo Giovanni¹⁶,Conti Giario¹⁷,Guida Michele¹⁸,Martignoni Guido¹⁹²⁰,Nolè Franco²¹,Pignata Sandro²²,Gori Stefania²³,Cartenì Giacomo²⁴

Affiliation:

1. Medical Oncology Unit, Azienda Ospedaliera Universitaria di Modena, Modena, Italy

2. Medical Oncology Unit, Azienda Ospedaliera S.Maria, Terni, Italy

3. Onco-Nephrology Outpatient Clinic, Division of Nephrology & Dialysis, San Carlo Borromeo Hospital, ASST Santi Paolo e Carlo, Milano, Italy

4. Romagna Cancer Registry, IRCCS, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), Meldola, Italy

5. Medical Oncology Division, Department of Clinical Medicine and Surgery, University Federico II of Naples, Napoli, Italy

6. Department of Urology, University of Florence, Careggi Hospital, Firenze, Italy

7. Ospedale Humanitas Mater Domini, Via Gerenzano 2, Castellanza, Varese, Italy

8. Department of Urology, S Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy

9. Medical Oncology Unit, AUSL-IRCCS di Reggio Emilia, Reggio Emilia, Italy

10. Section of Pathological Anatomy, United Hospital, School of Medicine, Polytechnic University of the Marche Region, Ancona, Italy

11. Oncology Department, ASL CN2 Alba, Bra (CN), Italy

12. Medical Oncology Department, ASST Cremona, Cremona, Italy

13. Department of Internal Medicine, University of Pavia and Division of Translational Oncology, IRCCS Istituti Clinici Scientifici Maugeri, Pavia, Italy

14. Medical Oncology-Genitourinary Unit, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milano, Italy

15. Department of Radiology, A. Cardarelli Hospital, Napoli, Italy

16. Epidemiology & Clinical Trials Office, General Hospital, Mirano (VE), Italy

17. Urology Unit, Azienda Socio-Sanitaria Territoriale Lariana, Sant’Anna Hospital, Como, Italy

18. Division of Medical Oncology; National Cancer Institute “Giovanni Paolo II”, Bari, Italy

19. Department of Diagnostic and Public Health, University of Verona, Italy

20. Department of Pathology, Pederzoli Hospital, Peschiera del Garda, Italy

21. Medical Oncology Division of Urogenital and Head & Neck Tumours, European Institute of Oncology, Milano, Italy

22. Department of Urology and Gynecology, Istituto Nazionale Tumori “Fondazione G. Pascale”, Napoli, Italy

23. Medical Oncology, IRCCS Sacro Cuore Don Calabria Hospital, Negrar-Verona, Italy

24. Department of Medical Oncology, Azienda Ospedaliero di Rilievo Nazionale “A. Cardarelli”, Napoli, Italy

Abstract

In the past two decades, the treatment landscape for patients with metastatic renal cell carcinoma has significantly changed thanks to the approval of several targeted molecular therapies (VEGF and mTOR inhibitors) and recently immune-checkpoint inhibitors. The Italian Association of Medical Oncology (AIOM) Renal Cell Cancer (RCC) Guidelines Panel has developed clinical guidelines to provide evidence-based information and recommendations to oncologists, urologists and all professionals involved in the management of patients with renal cell cancer.

Publisher

SAGE Publications

Subject

Cancer Research,Oncology,General Medicine

Link

http://journals.sagepub.com/doi/pdf/10.1177/0300891619853392

Reference94 articles.

1. Body mass index and risk of renal cell cancer: A dose-response meta-analysis of published cohort studies

2. Obesity, Hypertension, and the Risk of Kidney Cancer in Men

3. A Review of Von Hippel-Lindau Syndrome

4. Radiologic evaluation in planning surgery of renal tumors

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Noninvasive Pathological Staging of Clear Cell Renal Cell Carcinoma using Computed Tomography-based Radiomics Features and Machine Learning;2023 17th International Conference on Telecommunication Systems, Services, and Applications (TSSA);2023-10-12

2. The prognostic value of baseline and early variations of peripheral blood inflammatory ratios and their cellular components in patients with metastatic renal cell carcinoma treated with nivolumab: The Δ-Meet-URO analysis;Frontiers in Oncology;2022-09-23

3. RNA-seq and Mitochondrial DNA Analysis of Adrenal Gland Metastatic Tissue in a Patient with Renal Cell Carcinoma;Biology;2022-04-13

4. Long progression-free survival with cabozantinib in a heavily pretreated patient with metastatic renal cell carcinoma: a case report;Tumori Journal;2021-02-01

Acquired Hypothyroidism in Patients with Metastatic Renal Cell Carcinoma Treated with Tyrosine Kinase Inhibitors

;Drug Design, Development and Therapy;2020-09